Angiogenesis in Myocardial Ischemia: An Organized Review

  • Posted on: 25 November 2013
  • By: admin

 

PharmaTutor (November- 2013)

 

Received On: 18/10/2013; Accepted On: 03/11/2013; Published On: 25/11/2013

 

Authors:
Jalaram H Thakkar*, Ashiyana A Mansuri, Chirag Patel, Girish K Jani,
Department of Pharmacology,
SSR College of Pharmacy, Silvassa, Gujarat
*jay_143143@yahoo.com

 

ABSTRACT: The term Angiogenesis was coined by DR. John Hunter, a British surgeon in 1787. Later professor Judah Folkman gave the idea that growth of tumor depends on their blood supply and a new began research in this new field of therapeutics called ANGIOGENESIS.  Then, the identification of angiogenic growth factors, Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) fueled interest in using these factors in inducing therapeutic angiogenesis.[1] Initially angiogenesis was implicated only in few diseases like cancer, psoriases and arthritis. But, in recent years, it has been evident through a deep research that even excessive, insufficient and abnormal angiogenesis contribute to the pathogenesis of many disorders. Angiogenesis is regulated by a balance between pro- and anti- angiogenic factors. Research shows that angiogenesis and anti angiogenesis has given promising results in treatment of diseases like AIDS, atherosclerosis, ischemic heart disease and Alzheimer’s. In twenty first century, application of angiogenesis in therapeutics may have an impact on disorders similar to that which the discovery of antibiotics had in twentieth century.

 

How to cite this article: JH Thakkar,  AA Mansuri, C Patel, GK Jani, Angiogenesis in Myocardial Ischemia: An Organized Review, PharmaTutor, 2013, 1(1), 65-74

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML]